Jiangsu Lianhuan Pharmaceutical Co Ltd

Jiangsu Lianhuan Pharmaceutical Co Ltd has a debt-to-equity ratio of 1.28, indicating a moderate reliance on debt financing, and a current ratio of 0.98, suggesting limited short-term liquidity. The company's free cash flow is negative at -302.6 million CNY, and operating cash flow is also negative at -14.5 million CNY, signaling potential challenges in generating sufficient cash from operations.

Profitability metrics show a return on equity of -7.73% and a return on assets of -2.4%, both significantly below the industry median for pharmaceutical companies, which typically report positive returns. The company reported a net loss of 98.3 million CNY and an operating loss of 11.4 million CNY, indicating a decline in profitability.

The company's revenue is concentrated in a single geographic region, with all disclosed revenue generated in China. No segment-specific revenue breakdown is available, but the company operates in the pharmaceuticals industry, which is subject to regulatory and pricing pressures.

The company's revenue growth is not currently positive, and no specific growth trajectory is outlined in the available data. The operating loss and negative cash flows suggest a challenging operating environment, with no clear indication of improvement in the near term.

The company's risk profile includes medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt raises concerns about short-term financial stability. No recent dilutive events are reported, and the company has not issued new shares in the recent period.

No recent filings or transcripts are available in the provided data to indicate significant corporate events or strategic shifts. The company's financial performance and risk profile suggest a need for close monitoring of its liquidity and profitability trends.